Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma.

Next Previous
Trial Profile

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evofosfamide (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors IMMUNOGENESIS; Threshold Pharmaceuticals

Most Recent Events

  • 03 May 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012.
  • 28 Oct 2011 Results were reported at the Connective Tissue Oncology Society Meeting, according to a Threshold Pharmaceuticals media release.
  • 03 Aug 2011 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top